LUNG CANCER

The BR.31 trial found that adjuvant durvalumab did not improve disease-free survival in patients with non-small cell lung cancer, regardless of PD-L1 expression.

Pretreatment with dexamethasone significantly reduced infusion-related reactions in patients receiving amivantamab for advanced lung cancer, according to findings from the SKIPPirr study.

The trial previously met its primary end point of progression-free survival, and the final overall survival analysis was recently presented at the 2024 World Conference on Lung Cancer.

Firmonertinib showed efficacy and safety in patients with EGFR PACC-mutated non–small cell lung cancer.

The phase 3 KEYNOTE-867 and KEYNOTE-630 studies will be stopped due to futility, following analysis from independent data monitoring committees.

The phase 3 SOHO-02 trial has enrolled its first patient with advanced non–small cell lung cancer harboring activating HER2 mutations.

New data on zongertinib for HER2-positive non–small cell lung cancer will be presented at the IASLC 2024 World Conference on Lung Cancer, shedding light on its potential as a novel treatment option for this patient population.

The TruSight Oncology Comprehensive test has been approved by the FDA as a companion diagnostic for NTRK-fusion positive solid tumors and RET-fusion positive non–small cell lung cancer.

Biagio Ricciuti, MD, discussed findings from a retrospective study exploring the use of immune checkpoint inhibitors for longer than 2 years in patients with non–small cell lung cancer.

Byoung Chul Cho, MD, PhD, discussed findings from cohort C of the CHYRSALIS-2 study exploring amivantamab plus lazertinib in patients with non–small cell lung cancer with uncommon EGFR mutations.

Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.

The FDA has lifted the partial clinical hold on the phase 1 YL202-INT-101-01 trial, allowing enrollment to resume in the US for patients with advanced NSCLC harboring EGFR mutations and HR-positive/HER2-negative breast cancer.

In an interview with Targeted Oncology, Aristotelis Tsirigos, PhD, discussed a study evaluating a self-taught artificial intelligence tool that can accurately diagnose cases of adenocarcinoma.

PT217 has received an orphan drug designation from the FDA for the treatment of patients with neuroendocrine carcinoma.

The ON-SITE study has enrolled its first patient to evaluate an AI-based image analysis module for lung cancer.

The FDA-approved regimen is for neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable non–small cell lung cancer.

Following promising data from the phase 1 Deltacel-01 trial, the FDA has given Deltacel plus low-dose radiation therapy a fast track designation in stage IV non–small cell lung cancer.

In the Acclaim-1 and Acclaim-3 trials, prolonged progression-free survival and partial remission were observed with quaratusugene ozeplasmid plus osimertinib and atezolizumab for advanced lung cancer treatment.

The AFFINITY study has finished enrolling participants to evaluate the Aliya pulsed electric field system in patients with stage IV non–small cell lung cancer or lung metastases who are not candidates for surgery.

LP-300, a novel small molecule, shows promise as a potential breakthrough treatment for advanced non–small cell lung cancer in never smokers.

Suresh S. Ramalingam, MD, discussed the practice-changing findings and implications of the phase 3 LAURA study investigating osimertinib for the treatment of patients with EGFR-mutated non–small cell lung cancer.

During a Case-Based Roundtable® event, John V. Heymach, MD, PhD, talked with event participants about adverse events they have observed in their patients after using immune checkpoint inhibitors in the second article of a 2-part series.

While sacituzumab govitecan did not statistically improve overall survival vs docetaxel, there was a numerical improvement observed in patients with non–small cell lung cancer.

Nicolas Girard, MD, PhD, discussed findings from the PALOMA-2 study investigating subcutaneous vs intravenous amivantamab plus lazertinib for previously untreated, EGFR-mutant non–small cell lung cancer.

SenoVax, a novel senolytic immunotherapy for NSCLC, has been submitted as an investigational new drug application to the FDA, initiating a clinical trial to test its efficacy.